Latest news with #neurologicaldisorders
Yahoo
4 days ago
- Health
- Yahoo
Signs Of MS Can Appear 15 Years Before Diagnosis, Says Study—And Many Women Miss These Early Clues
It's easy to assume that you'd know when you're dealing with a disease as serious as multiple sclerosis. But it can take years for people with MS to get a proper diagnosis. Now, new research suggests that subtle symptoms of the disease may show up even 15 years before someone gets diagnosed with MS. In case you're not familiar with it, MS (multiple sclerosis) is a chronic condition where the body's immune system mistakenly attacks the protective covering of nerve fibers. People can experience a range of symptoms with MS, including vision problems, muscle weakness, tingling in the arms and legs, and muscle spasms, according to the National Institute of Neurological Disorders and Stroke (NINDS). Some people with MS will eventually develop partial or complete paralysis, per NINDS. The findings of the new JAMA Network Open study are shocking, and raise a lot of questions about how people can tell if their symptoms are due to something minor or a condition as serious as MS. Here's what neurologists want you to know. Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, MS, is the medical director in the Department of Neurology at Michigan State University. What did the study find? For the study, researchers analyzed the health records of about 2,000 people in British Columbia. They discovered that people who were eventually diagnosed with MS started interacting with the healthcare system more frequently 15 years before they first had symptoms that were later identified as being due to MS. Every person's health journey was different, but the researchers were able to pick up general trends. People who were eventually diagnosed with MS started seeing general practitioners more frequently 15 years before they were diagnosed for symptoms like fatigue, pain, dizziness, and mental health conditions like anxiety and depression. In the 12 years before their diagnosis, the patients saw a psychiatrist more often. Eight to nine years before a diagnosis, they had more frequent visits to neurologists and eye doctors, which may have been linked to blurry vision or eye pain. Three to five years before they were diagnosed, they visited the ER and had radiology visits more often. A year before their diagnosis, the patients saw physicians more often across a range of specialties, including neurology, emergency medicine, and radiology. This suggests 'that MS may have started earlier than previously thought,' the researchers wrote in the conclusion. Why might MS be so hard to detect this early? MS can look slightly different for everyone, and there is a wide range of symptoms, points out Amit Sachdev, MD, MS, medical director in the Department of Neurology at Michigan State University. MS is an autoimmune disease, and it can cause inflammation throughout the body, he explains. 'With excess inflammation, the body may feel generally dysfunctional,' Sachdev says. Meaning, you can feel lousy overall or in a lot of areas, making it hard for doctors (and you) to pin down what could be behind this. People with MS can also struggle with fatigue, which can be a tough symptom to tie to any one condition, Sachdev says. Symptoms like pain, mood changes, and fatigue tend to be linked more to an MS diagnosis after it's made, because they can be due to a range of health conditions, says Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. He says he tends to discover these symptoms when he looks back at patient's health history after an MS diagnosis. What should you do if you're having these symptoms? Doctors say it's a stretch to suggest that you should assume you have MS if you're only dealing with fatigue or mood changes. But Sachdev says you also shouldn't brush off symptoms that just don't quit. 'Health is deeply personal. To manage it, you need to begin with a provider that connects with you,' he says. 'Ideally, you would begin with a single observation or concern that is bothersome. Focusing on this issue with that provider is the place to start.' But Segil stresses the importance of seeing a specialist if you're dealing with several symptoms you really can't explain. 'Whenever you have a constellation of symptoms which are without a clear medical diagnosis, seeing a neurologist may be wise,' he says. They can help take a careful assessment of your health history, along with ordering testing, to see what could be going on. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Yahoo
6 days ago
- Health
- Yahoo
Signs Of MS Can Appear 15 Years Before Diagnosis, Says Study—And Many Women Miss These Early Clues
It's easy to assume that you'd know when you're dealing with a disease as serious as multiple sclerosis. But it can take years for people with MS to get a proper diagnosis. Now, new research suggests that subtle symptoms of the disease may show up even 15 years before someone gets diagnosed with MS. In case you're not familiar with it, MS (multiple sclerosis) is a chronic condition where the body's immune system mistakenly attacks the protective covering of nerve fibers. People can experience a range of symptoms with MS, including vision problems, muscle weakness, tingling in the arms and legs, and muscle spasms, according to the National Institute of Neurological Disorders and Stroke (NINDS). Some people with MS will eventually develop partial or complete paralysis, per NINDS. The findings of the new JAMA Network Open study are shocking, and raise a lot of questions about how people can tell if their symptoms are due to something minor or a condition as serious as MS. Here's what neurologists want you to know. Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, MS, is the medical director in the Department of Neurology at Michigan State University. What did the study find? For the study, researchers analyzed the health records of about 2,000 people in British Columbia. They discovered that people who were eventually diagnosed with MS started interacting with the healthcare system more frequently 15 years before they first had symptoms that were later identified as being due to MS. Every person's health journey was different, but the researchers were able to pick up general trends. People who were eventually diagnosed with MS started seeing general practitioners more frequently 15 years before they were diagnosed for symptoms like fatigue, pain, dizziness, and mental health conditions like anxiety and depression. In the 12 years before their diagnosis, the patients saw a psychiatrist more often. Eight to nine years before a diagnosis, they had more frequent visits to neurologists and eye doctors, which may have been linked to blurry vision or eye pain. Three to five years before they were diagnosed, they visited the ER and had radiology visits more often. A year before their diagnosis, the patients saw physicians more often across a range of specialties, including neurology, emergency medicine, and radiology. This suggests 'that MS may have started earlier than previously thought,' the researchers wrote in the conclusion. Why might MS be so hard to detect this early? MS can look slightly different for everyone, and there is a wide range of symptoms, points out Amit Sachdev, MD, MS, medical director in the Department of Neurology at Michigan State University. MS is an autoimmune disease, and it can cause inflammation throughout the body, he explains. 'With excess inflammation, the body may feel generally dysfunctional,' Sachdev says. Meaning, you can feel lousy overall or in a lot of areas, making it hard for doctors (and you) to pin down what could be behind this. People with MS can also struggle with fatigue, which can be a tough symptom to tie to any one condition, Sachdev says. Symptoms like pain, mood changes, and fatigue tend to be linked more to an MS diagnosis after it's made, because they can be due to a range of health conditions, says Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. He says he tends to discover these symptoms when he looks back at patient's health history after an MS diagnosis. What should you do if you're having these symptoms? Doctors say it's a stretch to suggest that you should assume you have MS if you're only dealing with fatigue or mood changes. But Sachdev says you also shouldn't brush off symptoms that just don't quit. 'Health is deeply personal. To manage it, you need to begin with a provider that connects with you,' he says. 'Ideally, you would begin with a single observation or concern that is bothersome. Focusing on this issue with that provider is the place to start.' But Segil stresses the importance of seeing a specialist if you're dealing with several symptoms you really can't explain. 'Whenever you have a constellation of symptoms which are without a clear medical diagnosis, seeing a neurologist may be wise,' he says. They can help take a careful assessment of your health history, along with ordering testing, to see what could be going on. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals Solve the daily Crossword
Yahoo
7 days ago
- Business
- Yahoo
BioVie Inc. Announces Pricing of $12 Million Public Offering
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), ('BioVie' or the 'Company'), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the 'Warrants') (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the 'Pre-Funded Warrants') and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). The gross proceeds to the Company from this offering are expected to be approximately $12 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants included in the units and pre-funded units have been approved for listing on the Nasdaq Capital Market and are expected to commence trading under the symbol 'BIVIW' on August 8, 2025. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $2.50 per share and will expire five years from the date of issuance. Each Pre-Funded Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock and may be exercised at any time until exercised in full. The common stock (or Pre-Funded Warrants in lieu thereof) and Warrants can only be purchased together in the offering but will be issued separately. The Company has granted the underwriter a 45-day option to purchase up to an additional 900,000 shares of common stock and/or Pre-Funded Warrants and/or Warrants, or any combination thereof, solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The Company intends to use the proceeds for working capital and general corporate purposes. The offering is expected to close on August 11, 2025, subject to satisfaction of customary closing conditions. ThinkEquity is acting as sole book-running manager for the offering. A registration statement on Form S-1, as amended (File No. 333-288525), relating to the securities was filed with the Securities and Exchange Commission ('SEC') and was declared effective on August 7, 2025. This offering is being made only by means of a preliminary prospectus forming a part of the registration statement and a final prospectus. The registration statement and the preliminary prospectus relating to the offering are available for free on the SEC's website at Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders Alzheimer's disease (AD) and Parkinson's disease (PD) and LongCovid (LC) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit Forward Looking StatementsThis press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein and are subject to a variety of risks and uncertainties, including but not limited to: expectations regarding the completion of the proposed offering; the Company's ability to successfully raise sufficient capital on reasonable terms or at all; available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends; our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates; our ability to successfully defend potential future litigation; and changes in local or national economic conditions. Various additional risks, many of which are now unknown and generally out of the Company's control, are detailed from time to time in reports filed by the Company with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Chuck Padala Managing Director, Investor Relations chuck@ For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@
Yahoo
07-08-2025
- Business
- Yahoo
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
Appointment to Chair of the Board and Additional Growth Funding Accelerate Longeviti's Mission in Developing Platform Solutions for Complex Neurological Disorders BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain disorders, today announces the appointment of Tim Scannell, former President & COO of Stryker Corporation, as Chair of its Board of Directors. The company also reveals a $10 million strategic capital partnership with Soleus Capital to accelerate hiring, product development, and medical education efforts in the United States and abroad. Scannell brings a wealth of experience in the medical device market having served in leadership positions with Stryker Corporation for over thirty years. He advanced from sales and marketing to executive leadership roles highlighted by ten years as Group President of MedSurg & Neurotechnology and three years as President and COO of Stryker. He was responsible for assisting in the selection and development of the strategies and talent that delivered over the last three decades and continues to deliver outstanding results today. Scannell is currently scaling MedTech businesses with his involvement as board representative and chair for multiple public and private companies, with the majority offering interaction with neurosciences and neurosurgeons. In his role as Chair, he will assist with formulating strategic plans and providing oversight while serving as a sounding board for management. Longeviti established a strategic capital partnership with Soleus Capital, a healthcare investment firm based in Greenwich, CT. The firm, which invests in the innovative areas of life sciences including medical technology, biotechnology, diagnostics, and life science tools, has committed $10 million in structured financing to fund key strategic priorities for Longeviti. With this capital, Longeviti is poised to accelerate talent acquisition needs, continued development of its groundbreaking neurotechnology platforms, expand its market presence, and continue delivering life-changing innovations that enhance patient care. 'Tim's appointment as Chair of the Board brings world-class leadership and unmatched insight from decades of success in building, and leading, high-performing MedTech companies. His experience will be instrumental as we sharpen our strategy and deepen our impact in neurotechnology. Coupled with the $10 million capital infusion from Soleus Capital, Longeviti now has the momentum to grow our team, advance critical research, and accelerate the development and delivery of life-changing solutions for patients with complex brain disorders,' shared Jesse Christopher, Co-Founder and CEO, Longeviti Neuro Solutions. 'I easily said 'yes' to joining the Board of Directors for Longeviti, mainly because of the talent. I've known several of Longeviti's leaders for years, and admire their tenacity, persistence, and goals to make an instrumental difference in the neuro industry. Longeviti's technology is revolutionary and will support the advancement of patient care in neurosciences, creating a value for the industry, our shareholders, and employees,' said Tim Scannell, Chair, Board of Directors, Longeviti Neuro Solutions and former President and COO, Stryker. 'I'm honored to share my experiences and opinions to support the success of Longeviti.' 'We were introduced to Longeviti by a respected key opinion leader who had firsthand experience using their innovative products in clinical practice. We were deeply impressed by the company's mission and strong operating results,' shared Ben Lund, Partner, Soleus Capital. 'It was clear to us that with the right capital support, Longeviti could scale its team, reach more clinicians and patients, and amplify its impact on those living with complex brain disorders. We are proud to be part of that growth.' About Longeviti Neuro Solutions ( Longeviti Neuro Solutions is a leading innovator in functional neurotechnology, dedicated to developing advanced solutions that improve the lives of patients with neurological conditions during and after surgery, while also returning them to anatomical normalcy. The Baltimore-based company has full manufacturing, packaging, designing, and sterilizing capabilities in-house with multiple FDA clearances, successful FDA audits, and ISO 13485 Certifications. Longeviti has 50 worldwide patents to date. Longeviti's mission is to develop innovative platform solutions for complex brain surgery. Its products are currently approved for use in over 120 hospitals across the globe. To date, Longeviti neurosurgical implants have helped over 4,000 patients. About Soleus Capital ( Soleus Capital is a healthcare investment firm based in Greenwich, CT. Founded in 2018, the company currently has ~$2B in assets under management. Soleus partners with companies across three strategies – public equity, private equity and structured credit – and across each of the life sciences subsectors – biotechnology, medical technology, life science tools and diagnostics. Contact: Nicole Halsey/Natalie Van Buskirk Polished Nichols PR & Marketing nicole@ natalie@ 410.952.2122/443.956.4765 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-08-2025
- Business
- Yahoo
Myomo to Report Second Quarter 2025 Financial Results on August 11
BURLINGTON, Mass., August 04, 2025--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter of 2025 on Monday, August 11, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call can be accessed at A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at A dial-in replay of the call will be available until August 25, 2025 at 877-344-7529 (U.S. toll free), 855-669-9658 (Canada toll free) or 412-317-0088 (International toll), using access code 4275362. About Myomo, Inc. Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally. For more information, please visit View source version on Contacts Myomo: ir@ Alliance Advisors IR: Tirth T. Pateltpatel@
